Merck & Co.'s CEO Kenneth Frazier expects his company to be a player in that lucrative hepatitis C market again with the anticipated approval this month of its hep C candidate. That, along with some M&A deals and growth in oncology should propel the world's fourth largest drugmaker forward for some time, he said this week.
Respiratory drugmakers have been looking to "smart inhaler" technology to give them a leg up on marketing in a crowded field. And Novartis wants a part of it.
Takeda Pharmaceutical CEO Christophe Weber is in the midst of crafting the Japanese company's turnaround, and a piece of that effort is Entyvio, a drug he says should chip in $2 billion at its peak. Weber will soon have a new biologics plant in the U.S. devoted in large part to that drug that will help that effort.
Pharma M&A is going strong so far this year, with Baxalta and Shire reportedly weighing a $32 billion-plus deal. But don't expect 2016 to best 2015 in terms of dealmaking, according to some industry watchers, who say that rapid-fire pace is likely to slow in the year ahead.
Actelion predicts it'll have a difficult time competing against its rivals for M&A targets going forward. But never fear. The company will have plenty to plow into its own development work thanks to its hefty price tag on new pulmonary arterial hypertension med Uptravi, execs said Tuesday.
Last week, Valeant CEO J. Michael Pearson, in the hospital with severe pneumonia, took a medical leave of absence. And now, the company is reportedly putting a new chief in his place.
It looks like Baxalta and Shire may be the first to keep pharma's red-hot M&A streak going in 2016, with a deal between the two rumored for as early as this week. But not everyone's convinced it's the right move.
Gilead Sciences already reaps billions from its hep C meds Sovaldi and Harvoni, but the company isn't content to sit back with the status quo. It's prepping a new hep C combo for FDA approval and recently got a boost after the agency granted the med a speedy review.
Generic powerhouse Teva Pharmaceutical Industries and Takeda said last year that they were working a deal to sell generics in Japan, a piece of the market expected to grow significantly as the government pushes off-patent drugs. Now the two have released details about how they will do that.
After patent expirations for big sellers Cymbalta and Evista, Eli Lilly managed to top analyst expectations in the first three quarters last year. But for 2016, the company expects to come in below where Wall Street thought it would be.
Sanofi and MannKind are calling it quits less than a year after pushing their inhaled insulin Afrezza onto a skeptical market. MannKind said today that the two will wrap up their business dealings on the drug within 6 months.
The world's largest animal health company is moving forward with its pledge to become a little less large. In its second deal in two weeks, Zoetis will sell a production site and some of its products in India to Zydus Cadila as part of its pledge to close 10 plants and cut about 2,500 employees as it strives to improve margins.
Activist investor and one-time Valeant deal partner Bill Ackman has been pretty gung-ho about the Canadian pharma as an investment prospect, even as controversy has battered its shares. Now, though, he's paring down his hedge fund's stake.
Vivus has never had a marketing partner for flailing obesity therapy Qsymia--and now, it's about to be one short for erectile dysfunction therapy Stendra, too. Last week, Endo's Auxilium Pharmaceuticals announced in a regulatory filing that it would be terminating its licensing pact--covering the U.S. and Canada--with the California drugmaker, with an end date of June 30.
2016 is the year that GlaxoSmithKline is supposed to start to show the results of CEO Andrew Witty's turnaround efforts. Well 2016 is here and Witty is expected to show up at the JP Morgan Healthcare Conference next week with plans he hopes will convince investors that his efforts to remake the British pharma giant have not been in vain.
The FDA is continuing its efforts to raise the standards of India's pharma industry, closing out the year with a warning to Cadila Healthcare, the company acknowledged in a report to the Bombay Stock Exchange. The citation follows warnings last year for a host of Indian drugmakers including Sun Pharmaceutical, Dr. Reddy's Laboratories and Mylan's sterile injectable operations in India.
Roche is burying the hatchet with India's Glenmark in a patent war over its cancer drug Tarceva, settling outstanding litigation with the company even as it wages a battle with another Indian generics maker over a patent for the med.
It's taken a months-long pursuit, but Shire is finally reportedly on the verge of nabbing target Baxalta.
Last week, Valeant confirmed that CEO J. Michael Pearson had been hospitalized with a severe case of pneumonia--and now, he's taking a medical leave of absence.
Drug prices were already a sore subject, but the pain grew this fall, when the now-former CEO of Turing Pharmaceuticals Martin Shkreli unapologetically jacked up the price of a 62-year-old drug by 5,000%-plus--to $750 per pill from $13.50. Unfortunately, that pain is going to continue into 2016.